Bruker Corporation (NASDAQ:BRKR) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $30.24 and last traded at $30.24, with a volume of 131,019 shares traded. The stock had previously closed at $29.99.

A number of brokerages recently weighed in on BRKR. BidaskClub cut shares of Bruker Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Cowen and Company reaffirmed a “hold” rating and issued a $29.00 price objective on shares of Bruker Corporation in a research report on Friday, July 14th. Barclays PLC reaffirmed an “equal weight” rating and issued a $30.00 price objective (up previously from $26.00) on shares of Bruker Corporation in a research report on Monday, July 17th. Zacks Investment Research upgraded shares of Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research note on Thursday, July 6th. Finally, Goldman Sachs Group, Inc. (The) reissued a “sell” rating and set a $24.00 target price on shares of Bruker Corporation in a research report on Tuesday, September 26th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $26.70.

The firm’s 50 day moving average is $29.04 and its 200 day moving average is $26.95. The stock has a market capitalization of $4.80 billion, a PE ratio of 30.14 and a beta of 1.09.

Bruker Corporation (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.03. Bruker Corporation had a return on equity of 26.66% and a net margin of 9.65%. The firm had revenue of $414.90 million for the quarter, compared to analyst estimates of $384.75 million. During the same period in the previous year, the company posted $0.20 earnings per share. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, equities research analysts anticipate that Bruker Corporation will post $1.12 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 22nd. Stockholders of record on Tuesday, September 5th were issued a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a dividend yield of 0.53%. The ex-dividend date of this dividend was Thursday, August 31st. Bruker Corporation’s payout ratio is presently 16.00%.

In other Bruker Corporation news, CEO Frank H. Laukien purchased 2,335 shares of the stock in a transaction on Thursday, August 10th. The shares were purchased at an average price of $27.39 per share, with a total value of $63,955.65. Following the acquisition, the chief executive officer now directly owns 37,791,386 shares of the company’s stock, valued at approximately $1,035,106,062.54. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Mark Munch sold 21,061 shares of the business’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total transaction of $631,198.17. Following the completion of the sale, the vice president now directly owns 60,524 shares in the company, valued at approximately $1,813,904.28. The disclosure for this sale can be found here. Corporate insiders own 35.20% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Bruker Corporation by 2.9% during the first quarter. Vanguard Group Inc. now owns 9,832,452 shares of the medical research company’s stock worth $229,391,000 after purchasing an additional 277,111 shares during the period. FMR LLC grew its stake in shares of Bruker Corporation by 26.4% in the 1st quarter. FMR LLC now owns 7,146,000 shares of the medical research company’s stock valued at $166,716,000 after purchasing an additional 1,491,140 shares during the period. BlackRock Inc. grew its stake in shares of Bruker Corporation by 3.0% in the 2nd quarter. BlackRock Inc. now owns 4,747,514 shares of the medical research company’s stock valued at $136,918,000 after purchasing an additional 139,792 shares during the period. Boston Partners grew its stake in shares of Bruker Corporation by 3.6% in the 2nd quarter. Boston Partners now owns 2,773,019 shares of the medical research company’s stock valued at $79,973,000 after purchasing an additional 96,791 shares during the period. Finally, Victory Capital Management Inc. grew its stake in shares of Bruker Corporation by 6.8% in the 2nd quarter. Victory Capital Management Inc. now owns 1,930,209 shares of the medical research company’s stock valued at $55,667,000 after purchasing an additional 123,322 shares during the period. Institutional investors and hedge funds own 65.42% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/03/bruker-corporation-brkr-reaches-new-12-month-high-at-30-24.html.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Receive News & Stock Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related stocks with our FREE daily email newsletter.